奥拉帕利联合替莫唑胺治疗晚期子宫平滑肌肉瘤的II期研究(NCI方案10250)
这项单臂、开放标签、多中心II期研究评估奥拉帕利联合替莫唑胺治疗既往至少一线进展的晚期子宫平滑肌肉瘤,22例可评估患者6个月内最佳客观缓解率为23%(5/22),总客观缓解率27%(6/22),中位无进展生存期6.9个月(95%CI 5.4个月至不可估计),达到预设主要终点。
要点
- 22例可评估患者6个月内最佳客观缓解率为23%(5/22),总客观缓解率27%(6/22)。
- 中位无进展生存期6.9个月(95%CI 5.4个月至不可估计)。
- 3/4级中性粒细胞减少75%、血小板减少32%,可通过剂量调整管理。
核心结论
- 奥拉帕利联合替莫唑胺达到预设主要终点,在晚期经治子宫平滑肌肉瘤中提供有意义的临床获益。
研究设计与样本
- NCI方案10250为单臂、开放标签、多中心II期研究,评估奥拉帕利联合替莫唑胺治疗晚期子宫平滑肌肉瘤。
- 患者既往至少一线治疗进展,接受替莫唑胺75 mg/m2口服每日一次联合奥拉帕利200 mg口服每日两次,均于21天周期的第1-7天给药。
- 主要终点为6个月内最佳客观缓解率,采用一阶段二项设计,若22例中≥5例缓解则认为治疗有前景(把握度93%;α=0.06)。
- 所有患者接受配对活检,行全外显子测序(WES)/RNA测序及RAD51聚焦形成检测。
主要发现
- 22例可评估,中位年龄55岁,59%接受过三线及以上既往治疗。
- 6个月内最佳客观缓解率为23%(5/22),总客观缓解率为27%(6/22)。
- 中位无进展生存期为6.9个月(95%CI 5.4个月至不可估计)。
- 血液学毒性常见:3/4级中性粒细胞减少75%,血小板减少32%,可通过剂量调整管理。
- WES显示16例中5例(31%)肿瘤携带有害同源重组基因改变,RAD51检测显示18例中9例(50%)为同源重组缺陷。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-tissue sarcoma with frequent metastatic relapse after curative surgery. Chemotherapy provides limited benefit for advanced disease. Multiomics profiling studies have identified homologous recombination deficiency in uLMS. In preclinical studies where olaparib and temozolomide provided modest activity, the combination was highly effective for inhibiting uLMS tumor growth. PATIENTS AND METHODS: NCI Protocol 10250 is a single-arm, open-label, multicenter, phase II study evaluating olaparib and temozolomide in advanced uLMS. Patients with progression on ≥1 prior line received temozolomide 75 mg/m2 orally once daily with olaparib 200 mg orally twice a day both on days 1-7 in 21-day cycles. The primary end point was the best objective response rate (ORR) within 6 months. A one-stage binomial design was used. If ≥5 of 22 responded, the treatment would be considered promising (93% power; α = .06). All patients underwent paired biopsies that were evaluated with whole-exome sequencing (WES)/RNAseq and a RAD51 foci formation assay. RESULTS: Twenty-two patients were evaluable. The median age was 55 years, and 59% had received three or more prior lines. Best ORR within 6 months was 23% (5 of 22). The overall ORR was 27% (6 of 22). The median progression-free survival (mPFS) was 6.9 months (95% CI, 5.4 months to not estimable). Hematologic toxicity was common (grade 3/4 neutropenia: 75%; thrombocytopenia: 32%) but manageable with dose modification. Five of 16 (31%) of tumors contained a deleterious homologous recombination gene alteration by WES, and 9 of 18 (50%) were homologous recombination-deficient by the RAD51 assay. In an exploratory analysis, mPFS was prolonged for patients with homologous recombination-deficient versus homologous recombination-proficient tumors (11.2 v 5.4 months, P = .05) by RAD51. CONCLUSION: Olaparib and temozolomide met the prespecified primary end point and provided meaningful clinical benefit in patients with advanced, pretreated uLMS.
引用
- Ingham M, Allred JB, Chen L, et al. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). J Clin Oncol. 2023. PMID: 37467452. doi:10.1200/JCO.23.00402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。